This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The study adds further evidence to the idea that drug copay cards are a great short-term deal for patients — and especially the pharmacompanies that promote them — but a wrong long-term value for healthcare costs. The post The drug industry continues to dare regulation appeared first on World of DTC Marketing.com.
Artificial intelligence (AI) is no longer a futuristic concept in healthcareits here, embedded in nearly every touchpoint of modern pharmamarketing. But as pharmamarketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster?
International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.
What has/is happening at Biogen is a train wreck, and the only way to correct this disaster is to tear it down and rebuild the company from the top down. ” To me, an enormous warning flag went up when the VP of Market Access was on a call with the commercial organization (sales). Click to Tweet.
N o one industry is ever quite like another, but there are some valuable lessons for pharmamarketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Engagement channels. Joanna Carlish. Content consistency.
?The CMA said some pharmaceutical firms charge the NHS with excessively high prices for hydrocortisone tablets and paid off potential competitors to stay out of the market.
If you work in pharma, the chances are you’re no stranger to the United States Food and Drug Administration, or FDA, which regulates pharmaceuticals. While the FDA is responsible for regulating both drugs and devices, they’re handled through completely different processes in different parts of the agency.
Earlier this year, I was asked by a client to write a position paper on using Facebook for the DTC marketing of an oncology product. A year ago, Facebook was making a hard charge to get the pharma business. TV will still be the first choice for many DTC marketers, but digital is increasing even though 50% of that money is wasted.
With increasing competition and stricter compliance regulations, pharmamarketing teams must adopt data-driven and personalized marketing strategies to capture the attention of HCPs. But how can pharma brands stand out in a crowded market? Key Marketing Strategies for Pharma Brands to Reach HCPs 1.
Table of Contents Sr# Headings 1 Introduction: The PharmaMarketing Challenge 2 Building a Winning PharmaMarketing Strategy 3 The Role of Branded Drug Campaigns 4 Innovating for Future Success Introduction: The PharmaMarketing Challenge Marketing pharmaceuticals is no small feat.
Bureaucracy, political upheaval, and lack of regulations continue to make Latin America a difficult market for European and North American pharma to enter – and COVID-19 has only worsened these issues. Developing market specialist Dr Zulf Masters OBE takes us through the nuances of being successful in this region.
I’ve seen some new energy and thinking taking root in some big pharmacompanies. Still, I’m also seeing some recycled executives show up at other companies when they should have been removed permanently from the industry. John worked for a division of a major pharmacompany in Cambridge.
As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. This is reinforced by web-focused marketing strategies that give them a highly-targeted approach when it comes to marketing execution.”. Be more agile .
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact.
The global pandemic has caused pharmacompanies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications.
It’s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to work towards approving drugs and vaccines in record times, the sector is also facing an influx of digital therapeutics and advanced drugs that don’t fit neatly into existing access frameworks.
The pharmaceutical industry is making significant strides toward sustainability, with companies across the sector implementing various Environmental, Social, and Governance (ESG) initiatives.
COVID-19 has disrupted markets and accelerated digital adoption but what does this mean for the future of marketing? In this feature, Grünenthal’s Florent Eduoard and Kate Hurtig outline their principles for a new pharmaceutical marketing model. . The R&D focus began to shift, and so did the marketing.
SUMMARY: Pharmacompanies, like J&J, have received criticism for engaging in illegal activities, such as providing kickbacks and bribes, knowingly shipping adulterated or contaminated drugs to pharmacies, and marketing drugs for unapproved uses. Johnson & Johnson has paid $2.7 billion in penalties. Ethical leadership!
Introduction Email marketing remains one of the most powerful tools for pharma brands , helping reach healthcare professionals (HCPs), patients, and stakeholders with tailored messaging. How can pharmamarketers craft high-performing email marketing campaigns while staying compliant?
Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. Capturing market share. billion by 2026, according to research by the Business Research Company.
In principle, the deal could create new opportunities for British pharmacompanies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.
The pandemic has required a rethink of how we do business: and CPhI Festival of Pharma is encouraging companies to prioritize sustainability efforts moving forward.
What is pharma’s responsibility? Pharma provides medications to treat everything from severe cardiac issues to depression but should America’s pharmacompanies go beyond just providing a treatment? People accuse pharma of keeping people sick to make money. Pha a fails in this. That’s a rumor.
The boom in digital tech over COVID means that pharma can move faster than ever – but the industry’s traditional processes for asset approval are still holding timelines back. David Reily examines how pharmacompanies are responding to the increased burden of asset approval with new ways of working. Bhupinder McJennett, AbbVie.
For pharmamarketers, these platforms provide an efficient way to reach doctors, caregivers, and patients while complying with strict regulations. With traditional digital marketing approaches becoming less effective, embracing data-driven, real-time advertising is no longer optionalits essential.
Pharmamarketing strategies have evolved significantly over the years, adapting to changes in technology, regulatory landscapes, and consumer behavior. This article provides a comprehensive overview of the various facets of pharmaceutical marketing, from its historical evolution to future trends.
When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. The “skinny label” has been used many times previously to enable ANDA applicants to reach the market in similar circumstances.
Location-based marketing, also known as geo-targeting, is an increasingly popular tool used in the pharmaceutical industry to reach customers in specific geographical areas. Geo-targeting allows pharmacompanies to customize their marketing efforts to reach the right customer at the right place and time.
Table of Contents Sr# Headings 1 Understanding Pharmaceutical Market Access 2 Challenges in Pharmaceutical Market Access 3 Key Strategies for Market Access Success 4 Emerging Trends Shaping Market Access Understanding Pharmaceutical Market Access Bringing a new drug to market is only part of the battle.
As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. This article explores the top pharmamarketing trends that are set to redefine the landscape in the coming years.
Introduction Pharmaceutical marketing has evolved. Social media advertising now plays a crucial role in reaching healthcare professionals (HCPs) and patients , allowing pharma brands to engage, educate, and build trust like never before. So, how can pharma brands maximize engagement while staying compliant ?
With millions of healthcare professionals (HCPs) and patients active on platforms like LinkedIn, Twitter, Facebook, and Instagram, pharma brands can no longer afford to stay silent. Effective social media strategies allow pharmacompanies to: Build trust with HCPs and patients. Short video clips with expert insights.
A new report from Access to Medicine Foundation gives the advice to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance.
In an era wher Pharmaceutical digital marketing is in the middle of a rapid transformation. For pharmamarketing executives , reaching audiences in meaningful, personalized ways has never been more critical. To put it simply, digital marketing in pharma is the bridge to reach these audiences effectively.
In the ever-evolving landscape of pharmaceutical marketing, the traditional methods of reaching healthcare professionals and consumers are gradually being supplemented by innovative digital strategies. In this context, influencer marketing can play a pivotal role in building and maintaining trust between pharmacompanies and their audiences.
The competition authorities in Switzerland said this morning they have carried out a raid on a pharmacompany – now confirmed to be Novartis – as part of an investigation into a “possible unlawful use of a patent to reduce competitive pressure.”
Marketers must adapt to cutting-edge technology, personalized engagement, and regulatory shifts to stay ahead. But what exactly is shaping the future of pharmamarketing this year? For example, pharma giants like Pfizer and Novartis leverage AI to optimize marketing outreach and drug commercialization.
The world of pharmamarketing is changing rapidly, and 2025 will be no exception. For pharmamarketing executives, adapting to these shifts isn’t just about keeping up—it’s about staying ahead. So, what will be the top challenges in 2025, and how can pharmamarketers tackle them?
The world of digital marketing in pharma is evolving rapidly. Pharmamarketing executives face the unique challenge of staying compliant while engaging audiences in meaningful ways. So, how can digital marketing truly revolutionize the pharma space? Today, a patient-centric approach is essential.
Marketingpharma has become a complex and competitive field, with companies vying for the attention of healthcare providers (HCPs), patients, and regulators alike. Understanding the Challenges in MarketingPharmaMarketingpharma isn’t without its challenges. The good news?
The HIV-focused pharmacompany announced the agency has approved Cabenuva for administration as few as six times a year for adults living with the virus.
Rows about vaccine supply and threats of export blocks donât do anything to bring us closer to ending the COVID-19 pandemic, say campaigners pushing for vaccine equity on a global level.
The new guidance is the first of a series that have been promised by the US regulator to develop a framework for regulating RWD, which is increasingly being used by pharmacompanies to investigate how their medicines perform beyond the controlled environment of clinical trials.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content